Inclusion Criteria:

          -  Life expectancy of at least 12 weeks

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Measurable disease is defined as at least one bi-dimensionally measurable non-lymph
             node lesion greater than or equal to (>/=) 1 centimeter (cm) on long access diameter
             on computed tomography (CT) or magnetic resonance imaging (MRI) scan or at least one
             bi-dimensionally measurable lymph node measuring >/=1.5 cm on short access diameter on
             CT or MRI scan

          -  Adequate hematologic, kidney and liver function

          -  Highly effective contraception as defined by the protocol Participants with Ovarian
             Cancer

          -  Histological documentation of epithelial ovarian cancer, primary peritoneal cancer, or
             fallopian tube cancer

          -  Documentation of mucin 16 (MUC16) expression by either serum carcinoma antigen 125
             (CA125) >=2 x Upper limit of normal (ULN) or by immunohistochemistry [IHC] by central
             review

          -  Disease that has progressed or relapsed during or within 6 months after the most
             recent treatment with a platinum-containing chemotherapy regimen

          -  Progression or relapse from prior platinum-based chemotherapy must be documented
             radiographically by RECISTv1.1 criteria

        For ovarian cancer dose expansion cohorts only:

          -  Not more than two prior chemotherapy regimens for the treatment of platinum-resistant
             ovarian cancer

        Participants with Pancreatic Cancer:

          -  Histologic documentation of incurable, locally advanced, or metastatic pancreatic
             ductal adenocarcinoma consisting of unresectable pancreatic ductal adenocarcinoma
             (i.e., participants who are not considered eligible for surgical resection with
             curative intent), including recurrence of previously resected disease

          -  Documented MUC16 expression from archival or fresh tissue by IHC central review

          -  Participants for whom no further standard of care therapy exists, must have received
             standard of care chemotherapy in the adjuvant or advanced/metastatic setting

          -  No more than two prior chemotherapy regimens administered for the treatment of
             pancreatic cancer in the adjuvant or advanced/metastatic setting

        Exclusion Criteria:

          -  Anti-tumor therapy, including chemotherapy, biologic, experimental, or hormonal
             therapy within 4 weeks prior to Day 1

          -  Prior treatment with MUC16 targeted therapy (e.g., oregovomab [OvaRex] or abagovomab)
             including DMUC5754A

          -  Prior treatment with a monomethyl auristatin E (MMAE)-containing antibody-drug
             conjugate (ADC)

          -  Palliative radiation to bone metastases within 2 weeks prior to Day 1

          -  Prior radiation to lung fields

          -  Major surgical procedure within 4 weeks prior to Day 1

          -  Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection
             (including human immunodeficiency virus [HIV] and atypical mycobacterial disease but
             excluding fungal infections of the nail beds) at study enrollment or any major episode
             of infection requiring treatment with IV antibiotics or hospitalization (relating to
             the completion of the course of antibiotics) within 4 weeks prior to Cycle 1, Day 1

          -  Evidence of significant uncontrolled concomitant diseases, such as ocular toxicities,
             diabetes, cardiovascular disease; nervous system, renal, hepatic, endocrine, or
             gastrointestinal disorders; autoimmune disease, or a serious non-healing wound or
             fracture

          -  Clinically significant pulmonary symptoms and signs, any active pulmonary or
             respiratory infection at enrollment, pulmonary infiltrates on screening CT scan of the
             chest that are associated with symptoms (including dyspnea), resting or exercise
             arterial oxygen saturation (SpO2) less than (<) 90 percent (%), requirement for
             supplementary oxygen at rest or exercise (either continuously or intermittently),
             moderate (40%-60% predicted) or severe (<40% predicted) decreased diffusing capacity
             for carbon monoxide (DLCO) or mild (>60% </= lower limit of normal [LLN]% predicted)
             decrease with clinically significant symptoms

          -  Clinically significant history of liver disease, including viral or other hepatitis,
             current alcohol abuse, or cirrhosis

          -  Other malignancy within the last 5 years, except for adequately treated carcinoma in
             situ of the cervix, squamous carcinoma of the skin, adequately controlled limited
             basal cell skin cancer, or synchronous primary endometrial cancer or prior primary
             endometrial cancer if protocol criteria are met

          -  Untreated or active central nervous system (CNS) metastases. Participants with a
             history of treated CNS metastases may be eligible

          -  Current Grade greater than (>) 1 toxicity (except alopecia and anorexia) from prior
             therapy or Grade >1 neuropathy from any cause

          -  History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
             (or recombinant antibody-related fusion proteins)

          -  Pregnancy or breastfeeding

          -  Inability to comply with study and follow-up procedures

          -  Any other diseases, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or that may affect the
             interpretation of the results or render the participants at high risk from treatment
             complications